Zydus Lifesciences Limited (ZYDUSLIFE) — Financial Results | 12 August 2025(4 announcements)

Zydus Lifesciences filed a disclosure notification on August 12, 2025, regarding the availability of an audio recording from its investor call discussing unaudited financial results for the quarter ended June 30, 2025. The filing is a regulatory compliance document under SEBI Listing Regulations, directing shareholders to access the call recording on the company's investor relations website. No financial metrics or material business updates are disclosed in this filing.

Zydus Lifesciences reported Q1 FY26 revenues of ₹65,737 million, growing 6% YoY, with net profit at ₹14,668 million (3% YoY). EBITDA margin remained flat YoY at 31.8%. India formulations grew 8% driven by chronic portfolio strength, while International Markets surged 37%. US formulations grew 3% YoY on a high base. Consumer Wellness faced monsoon headwinds but showed 2.2% YoY growth. Net cash improved to ₹56,312 million from ₹48,836 million in Q4 FY25.

Zydus Lifesciences Limited held its 30th Annual General Meeting on August 12, 2025, with 74.97% shareholder attendance. All 7 resolutions passed overwhelmingly, including approval of standalone and consolidated financial statements (99.97% in favor), declaration of a ₹11 per share final dividend (1100%), re-appointment of directors Dr. Sharvil P. Patel and Ganesh N. Nayak, and appointment of auditors. Director Nayak's 5-year employment extension includes ₹36 million annual remuneration.

Zydus Lifesciences reported Q1 FY26 consolidated revenue of ₹65,737 million, up 6% YoY, with net profit of ₹14,668 million, up 3% YoY. EBITDA remained flat at ₹20,885 million with a margin of 31.8%. International Markets formulations surged 37% YoY, while US formulations grew 3% YoY. R&D spending reached ₹4,856 million (7.4% of revenues). The company advanced its innovation pipeline with biosimilar approvals and initiated Phase II trials for Usnoflast, an NLRP3 inhibitor for ALS.